Cord Blood America, Inc.

Cord Blood America (OTC BB: CBAI) Argentina Revenues Up 40 Percent

2011-09-27T22:28:06+00:00

Cord Blood America Updates Shareholders on Argentina

LAS VEGAS and BUENOS AIRES, Argentina, September 27, 2011. PRNewswire - Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, today updated shareholders on the progress of Biocordcell Argentina S.A. (BioCells, Inc.), which is 50.1 percent owned by Cord Blood America.

"January through August revenues in 2011 are up 40 percent to $1.18 million (U.S.)," said Diego Rissola, president of BioCells, Inc. "The increase in revenues reflects the fact that we have established franchises in six provinces in Argentina and we opened an office in Miami, Florida, to service the Latin American population there. We are now signing 11 percent more new contracts than we did in the same period in 2010." "We have been successful with e-marketing, using a new web page and social media. We also now have operations in Brazil and the Dominican Republic, and the development of storing dental pulp is proving to be a potential revenue enhancer for the Company," Mr. Rissola said.

"BioCells of Argentina has performed fantastically in a down global economy. We've realized great growth, profitability, just a good story all around. We're fortunate to have purchased the control position of this ever expanding company," said Matthew Schissler, CEO of Cord Blood America.

(Revenue and other financial estimates contained in this press release have not been audited or reviewed by Cord Blood America's independent auditors. The Company provides no assurance that these preliminary results will not change following the completion of its financial audit for Fiscal 2011.)

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI.ob - News) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board:CBAI.ob - News), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

CONTACT

Paul Knopick
E & E Communications
949.707.5365
pknopick@eandecommunications.com

SOURCE Cord Blood America, Inc.

Web Site: www.cordblood-america.com

Web Site: www.corcell.com

Cord Blood America (OTC BB: CBAI) Laboratory Update

2011-09-20T00:43:46+00:00

Cord Blood America Updates Investors on Laboratory Licensing

LAS VEGAS, September 19, 2011. PRNewswire - Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, is pleased to announce that it has received all State licenses and Federal registrations required to operate as a cord blood bank in the United States.

These licenses include licenses from the State of New York as a Tissue bank, the State of New Jersey as a Blood Bank, the State of Maryland as a Tissue Bank and the State of California for the Production of Biologics. Also, Cord Blood America's laboratory is a Registered Laboratory in the State of Nevada in areas of Bacteriology and Hematology. Federal registrations include the U.S. Food & Drug Administration (FDA ) as well as CLIA ( Clinical Laboratory Improvement Amendments). Cord Blood America, is preparing for ISO 9001 certification and for American Association of Blood Banks accreditation in 2012. BioCells, its Argentina-headquartered stem cell company, recently received its ISO 9001 certification.

"CBAI is committed to maintaining the highest quality of standards for our lab processing, including physician preferred sterile Pall medical bags used in our collection kits, which most of competitors do not have, and the BioE processing system which has in the latest studies shown the highest recovery in hematopoietic stem cells compared to other harvesting systems," said Dr. Geoffrey O'Neill , Vice President.

"What gets lost in all of the activity of CBAI is the communication of our fundamental execution. As mentioned, we are focused on the business fundamentals right now. We are pleased that we have met all of the stringent requirements necessary to obtain the current licenses. There is always more work to do, new licenses to get, and updates of existing licenses," commented Matthew Schissler, co-founder and CEO.

A new video developed by the Nevada Commission on Economic Development, contains excellent shots of the Company's stem cell laboratory facility in Las Vegas: Nevada Commission on Economic Development

The Company also announced that Cord Blood America has accepted an invitation to present at the 7th Annual Stem Cell Summit, an intensive one-day event, allowing attendees to learn about the latest developments in the stem cell marketplace, evaluate groundbreaking stem cell products and discover the growing market potential in terms of revenues. The Summit will be held on Feb 21, 2012 at Bridgewaters in New York City's historic South Street Seaport.

About Cord Blood America

CONTACT:
Paul Knopick
E & E Communications
949-707-5365
pknopick@eandecommunications.com

SOURCE Cord Blood America, Inc.

Cord Blood America (OTC BB: CBAI) Explains Financial Fundamentals are Strong

2011-09-15T22:26:21+00:00

Cord Blood America CEO Statement to Shareholders

LAS VEGAS, September 15, 2011

Dear Fellow Cord Blood America Shareholders:

We receive e-mails, calls or other forms of communications daily concerned about our stock price. We share that concern. Please know that your management teams also are shareholders and seeing the current market value is disappointing to all of us.

We are disappointed that the market currently does not recognize the very strong fundamentals of our Company. It does not value our achievements, as it did in previous years passed. We know it is important to continually communicate our positive accomplishments...and I promise to you that we will not quit. Ever.

In the last two years we have worked diligently to grow the company. We believe our numbers reflect that effort. Organic growth, acquisitions and diversification of revenue streams have been our mantra. Our credibility was execution on those three, and I feel to a large extent, we achieved that. However the share price does not reflect it, and, ultimately, I vow that we will spend every day working to restore a share price that more accurately reflects the fair value of the Company today, and in the future.

I would like to address in this note issues concerning the Present Value of our Company. Frankly, we should be valued well above our current market cap. Yes, all management teams say that, however, our data truly reflects an undervaluation. These are some of the key reasons:

* The net present value of our annual storage revenues alone, not including any new business whatsoever, while in a down market is still worth over $11,000,000 and can be argued much higher than this number.

* Total revenue due to us over the next 18 years from annual storage agreements alone, again, not inclusive of any new business, estimated to be in excess of $25,000,000

* 61% positive revenue growth in first six months of 2011

* 100% positive gross profit growth in same time period coupled with ever increasing gross margin percentages

* 37% loss reduction in same time period

* A strong organic growth engine adding 15 new insurance company contracts in the past 12 months

* Tracking towards total revenues of $6,000,000. Domestic sales hit highest levels in an August month since 2007 and trends indicate more positive outcomes for September. We have added 15 new insurance contracts in 2011. While they take time to bear fruit, we are hopeful we are seeing the beginning of this effort

* Cost controls that more closely align revenues with expenditures for all operations. Company anticipates the quarterly narrowing of operational losses in Q3 and Q4 from Q1 and Q2 levels. We saw a normalized market value of $25M consistent for over one year in 2009-2010 for our Company when we were much smaller. We have been active in the acquisition market now for several years, and we can tell you that

* A large competitor with worse financials but strong market valuation realized 5x revenues for their company when they exited the market

* Even in distressed situations, companies can receive a minimum of $300 per contract which would put our value at a very minimum over $9M. Again, this is no goodwill or additional component valued for organic growth

To put it another way, our fundamentals are strong and this Company, truly, has never been in better financial shape. A man I admire, Bill Polian, Vice Chairman of the Indianapolis Colts who has had tremendous success in the NFL for many decades, routinely says, and I'll paraphrase, that "the only thing the team is concerned with is the 53 men on the field and the employees in the building, getting them better, stronger and ready to play weekly. If you focus on the fundamentals, everything else falls into place." I feel the same way: focus on the people at our lab in Las Vegas, our lab in Argentina, our office in Germany, our investments in China and Spain. Focus on our financials, our quality products, diversification of revenues, and healthy organic business. Focus on the fundamentals, and the rest will take care of itself.

I'd like to reflect back for a moment on why we started this Company. What we market is similar to an insurance policy, conveying a strong peace of mind. We believed then, and we believe even more today, that stem cells will play a key role in launching a new era of medicine, an era in which we are finally successful against some of the most intractable diseases mankind faces. Cryogenically preserved umbilical cord blood stem cells have already been used to successfully treat 75 major diseases, including leukemia, severe anemia, metabolic blood disorders and immune deficiencies. What is so amazing is that in laboratories across our globe stem cells are being studied for use against stroke, spinal cord injuries, heart disease, Parkinson's disease, multiple sclerosis, diabetes and almost any disease you can name which now cannot be cured. One breakthrough in one of these laboratories is going to make stem cells one of the hottest sectors in the entire market, of that I am convinced. Researchers dream that the cells they remove from umbilical cord blood can someday be turned into any single tissue in the body, allowing for the repair of a damaged heart or a brain ravaged by a stroke.

Has this been a difficult period? Yes. Every company that grew from an idea at the kitchen table to a power in its sector has had difficult periods. But I want to make this promise clear to our shareholders: We will not quit. We will work every day to improve the quality of the Company, confident that someday this will be recognized by the marketplace. For those of you who have stuck with us for years, our heartfelt thanks. We recognize many of you have followed our news and are looking for more. During the time of undervaluation, our focus is fundamentals. The news will come, it always has. Better to be opportunistic than to force action. Please know the sweat equity we pour into this company every day to someday realize the true valuation of our growing business.

Sincerely,

Matthew L. Schissler

Chairman, Co-Founder and CEO

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect,'' "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Cord Blood America's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

About Cord Blood America

CONTACT

Paul Knopick
E & E Communications
949.707.5365
pknopick@eandecommunications.com

SOURCE Cord Blood America, Inc.

Web Site: www.cordblood-america.com

Cord Blood America (OTC BB: CBAI) Begins Storing Bone Marrow Stem Cells Prior to Cancer Treatment

2011-08-31T21:56:10+00:00

Cord Blood America Announces New Service for South American Storage Company: Storing Bone Marrow Stem Cells Prior to Cancer Surgeries

LAS VEGAS, August 31, 2011. PRNewswire - Cord Blood America, Inc. Cord Blood America, Inc. (OTC Bulletin Board:CBAI.ob - News), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced that Biocordcell Argentina S.A., headquartered in Buenos Aires, its stem cell storage company which services South America and Miami, Florida, has begun storing bone marrow stem cells prior to transplantation in treatments for cancer.

"The storage is short term, for three months or less, and it is done at a hospital in Buenos Aires," said Diego Rissola, President of BioCells Argentina. "It is important since it diversifies our revenue stream, contributes to the fight against cancer, and emphasizes the quality and reputation of our storage company."

"We are pleased to see our international companies be aggressive in increasing revenues and in utilizing new ideas to promote gross profits," said Matthew Schissler, Cord Blood America CEO and co-founder. "Diversification of revenues has been one of our three pillars of success for the last two years. In that time CBAI's group of companies have launched placental stem cell collection services, whole umbilical cord tissue collection services, dental pulp stem cell storage services, and now bone marrow stem cell storage services. These services have partly contributed to our increase in revenues, as reported in our last two Form 10Q filings with the United States Securities and Exchange Commission, including the 61% year over year revenue increase reported for second quarter 2011."

About Cord Blood America

CONTACT

Paul Knopick
E & E Communications
949.707.5365
pknopick@eandecommunications.com

Cord Blood America (OTC BB: CBAI) Now Banking Stem Cells in Puerto Rico, the Caribbean

2011-08-29T22:41:44+00:00

Cord Blood America Enters Agreement With BancoVida, a Cord Blood Collection Company in San Juan, Puerto Rico

LAS VEGAS, August 29, 2011. PRNewswire - Cord Blood America, Inc. (OTC Bulletin Board: CBAI) announced today it has entered into an agreement with BancoVida (www.bancovida.com) to offer umbilical cord blood collection services in Puerto Rico and throughout the Caribbean.

The partnership will allow BancoVida and Cord Blood America to educate prospective parents in Puerto Rico and the Caribbean on the value of storing their baby's umbilical cord blood. The stem cells will be stored at Cord Blood America's state-of-the-art facility in Las Vegas.

"We are very excited about our partnership with BancoVida and for the opportunity to assist them in bringing this potentially life-saving service to an underserved area," said Gabby Stinson, Cord Blood America Project Manager.

Cord blood stem cells, which are collected at birth in a non-invasive procedure, are currently used to treat more than 70 diseases including leukemia, severe anemia, metabolic blood disorders and immune deficiencies. Various studies and clinical trials are currently underway to determine the effectiveness of stem cells in treating some of the most serious diseases, such as diabetes, heart disease, Parkinson's and cerebral palsy for which there is no known cure.

About BancoVida

BancoVida Corp. has been established to develop and market private cord blood banking services to patients in Puerto Rico and the Caribbean. Our mission is to successfully introduce and become the leader of private cord blood banking in the Caribbean. BancoVida is the exclusive reseller of cord blood banking services for Cord Blood America and CorCell in Puerto Rico and the Caribbean. To find out more about BancoVida, visit our website at www.bancovida.com.

About Cord Blood America

Paul Knopick
E & E Communications pknopick@eandecommunications.com
949.707.5365

SOURCE Cord Blood America, Inc.

Web Site: www.cordblood-america.com

Web Site: www.corcell.com